Related Experiment Video

Updated: Oct 14, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

Small Molecules Targeting Activated Cdc42-Associated Kinase 1 (ACK1/TNK2) for the Treatment of Cancers

Aoxue Wang1, Junping Pei1, Wen Shuai1

  • 1State Key Laboratory of Biotherapy and Cancer Center, Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, National Clinical Research Center for Geriatrics, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China.

Journal of Medicinal Chemistry
|November 4, 2021
PubMed

Insights

Activated Cdc42-associated kinase 1 (ACK1) is a key factor in cancer development and progression. Targeting ACK1 with small molecule inhibitors shows promise for cancer therapy, though clinical trials are still pending.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Activated Cdc42-associated kinase 1 (ACK1/TNK2) is a nonreceptor tyrosine kinase with a crucial role in signal transduction and epigenetic regulation.
  • ACK1 functions as a transmembrane effector for receptor tyrosine kinases (RTKs), mediating diverse RTK signaling pathways.
  • ACK1 has been identified as a significant carcinogenic factor, implicated in promoting cancer cell survival, proliferation, migration, and radiation resistance.

Purpose of the Study:

  • To provide a comprehensive overview of the structural characteristics, biological functions, and disease associations of ACK1.
  • To review the in vitro and in vivo activities, selectivity, and therapeutic potential of various small molecule ACK1 inhibitors.
  • To highlight ACK1 as a promising target for novel antitumor therapies.

Main Methods:

  • Literature review and analysis of existing studies on ACK1.
  • Examination of structural features and biological functions of ACK1.
  • Evaluation of in vitro and in vivo data for small molecule ACK1 inhibitors across different chemotypes.

Main Results:

  • ACK1's unique structure enables its dual role in RTK signaling and epigenetic regulation.
  • Inhibition of ACK1 demonstrates significant anti-cancer effects, including reduced cell survival, proliferation, and migration.
  • Various small molecule inhibitors targeting ACK1 have shown promising in vitro and in vivo activities and selectivity profiles.

Conclusions:

  • ACK1 is a validated target for cancer therapy due to its oncogenic functions.
  • Despite challenges, the development of small molecule ACK1 inhibitors holds significant therapeutic potential for various cancers.
  • Further research and clinical trials are warranted to translate these findings into effective cancer treatments.

More Related Videos

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.6K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.2K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
15.0K